Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cellceutix Signs CDA for Autism Drug | Contract Pharma

What are you searching for?

Sign in
Breaking News

Cellceutix Signs CDA for Autism Drug

Cellceutix Corp. has entered into a Confidential Disclosure Agreement (CDA) with a large pharmaceutical company for KM-391, its novel compound being developed as a treatment for autism.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cellceutix Corp. has entered into a Confidential Disclosure Agreement (CDA) with a large pharmaceutical company for KM-391, its novel compound being developed as a treatment for autism.

Cellceutix chief executive officer, Leo Ehrlich, commented, “This is simply another vote of confidence from large pharma as to the strength of our pipeline and a testament to the attention that we are receiving on a global level. While signing a CDA does not imply or guarantee that a licensing deal or any other transaction will happen, it is important in the sense of industry recognition of our compounds, as the signing of a CDA this early in development is generally a very rare occurrence.”

Cellceutix’s formulation manufacturer, Formatech, has completed production of Kevetrin for use in trials. Kevetrin is a compound targeting lung, breast, colon and other cancers not responding to existing drug therapies. Cellceutix is on schedule to file its IND with the FDA in May 2011.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters